Fecal Microbiota Transplantation as a Novel Therapy for Ulcerative Colitis

A Systematic Review and Meta-Analysis

Dali Sun, MD, Weiming Li, PhD, Shumin Li, MD, Yunyun Cen, MD, Qingwen Xu, MD, Yijun Li, MD, Yanbo Sun, MD, Yuxing Qi, MD, Yueying Lin, MD, Ting Yang, MD, Pengyuan Xu, MD, and Qiiping Lu, PhD

Abstract: Variation in clinical evidence has prevented the adoption of fecal microbiota transplantation (FMT) in patients with ulcerative colitis (UC). We aimed to conduct a systematic review and meta-analysis to determine the efficacy and safety of FMT in UC.

A systematic literature search was performed in 5 electronic databases from inception through September 2015. Inclusion criteria were reports of FMT in patients with UC. Studies were excluded if they did not report clinical outcomes or included patients with infections. Clinical remission (CR) was defined as the primary outcome.

Eleven studies (2 randomized controlled trials (RCTs), 1 open-label case-control study, and 8 cohort studies) with a total of 133 UC patients were included in the analysis. In 11 studies (including 8 noncontrol cohort studies and the treatment arms of 3 clinical control trials), the pooled proportion of patients who achieved CR was 30.4% (95% CI 22.6–39.4%), with a low risk of heterogeneity (Cochrane Q test, \( P = 0.139; I^2 = 33\%\)). A subgroup analysis suggested that no difference in CR was detected between upper gastrointestinal delivery versus lower gastrointestinal delivery. Furthermore, subgroup analysis revealed that there was no difference in CR between single infusion versus multiple infusions (>1) of FMT. All studies reported mild adverse events.

FMT is potentially useful in UC disease management but better-designed RCTs are still required to confirm our findings before wide adoption of FMT is suggested. Additionally, basic guidelines are needed to identify the right patient population and to standardize the process of FMT.

INTRODUCTION

Ulcerative colitis (UC) is a chronic, relapsing, and remitting disease characterized by inflammation of the colonic mucosa. UC is a subtype of inflammatory bowel disease (IBD) causing significant morbidity. Epidemiological studies have shown a significant increase in the incidence of UC across the world (about 3 million of people).\(^1\)\(^2\) While the precise etiology of UC remains unclear, several risk factors including immunologic, genetic, environmental, and gut microbial have been proposed. Several studies have suggested that gastrointestinal microbiota might play a role in development of this disease.\(^3\) Specifically, microbial dysbiosis has been hypothesized as a trigger in UC disease development.\(^4\)

Treatments that manipulate the microbiota balance have been developed and investigated including the administration of probiotics and prebiotics, with different evidences observed for their efficacy.\(^5\)\(^6\) An additional alternative therapy for the management of UC is fecal microbiota transplantation (FMT), which has been shown as an effective treatment for refractory and recurrent *Clostridium difficile* infection (CDI).\(^7\) The success of FMT in treating *C difficile* infections has raised the possibility that FMT may be beneficial in other diseases through alterations in gastrointestinal microbiota or dysbiosis.

The use of FMT in UC patients was first described by Bennet in 1989.\(^8\) In this case, Bennet treated himself, an active and severe UC patient, using FMT and he was symptom-free for 6 months subsequently. Afterward, other reports were published, most of which were case reports or noncontrol cohort studies, with variable results. Recently, some new cohort studies\(^9\)–\(^13\) and the first 2 randomized, double-blinded, controlled trials\(^14\)–\(^15\) were presented, but the findings in these studies are variable which has unfortunately confused UC clinicians.

Only 1 meta-analysis of IBD included both unpublished and abstract data including 1 abstract of RCT.\(^16\) Additionally only 4 noncontrol cohort studies of UC patients with FMT (27 cases) were performed in a subgroup analysis that showed a pooled estimate for achieving remission of 24.1% (95% CI 11.1–44.9%). The validity of that data was limited by the methodological concerns and the lack of an adequate number of studies.\(^16\) Three systematic reviews of IBD also included some case reports and noncontrol cohort studies of UC patients.\(^17\)–\(^19\) but also contained...
several methodological limitations. In fact, 2 systematic reviews did not analyze the subgroup of UC,\textsuperscript{17,18} while 1 systematic review contained mostly case reports and FMT outcomes that were measured by treatment “success rates” and not by any other more validated measures.\textsuperscript{19}

The aim of this study was to undertake a systematic review and meta-analysis of FMT in patients with UC so as to provide clinicians with a comprehensive and clear assessment of the available evidence upon which to guide current practice and future research.

METHODS

Search Strategy

We followed the MOOSE, PRISMA, and Cochrane guidelines in our study.\textsuperscript{20–22} An electronic search was conducted using PubMed, Cochrane Library, Web of Science, Wanfang Data, and China National Knowledge Infrastructure. All databases were searched from their inception through September 2015. No language limits were used. Searching was limited to publications with clinical trials (RCTs, case-control trials and cohort studies). In concurrence with Colman and Rubin,\textsuperscript{10} both free text and medical subject headings of this study included the following alternatives for fecal microbiota transplant: “fecal transplant,” “fecal transfusion,” “fecal implantation,” “fecal implant,” “fecal instillation,” “fecal donor,” “fecal enema,” “fecal reconstitution,” “fecal infusion,” “fecal therapy,” “fecal bacteriotherapy,” “faecal transplant,” “faecal transfusion,” “faecal implantation,” “faecal implant,” “faecal instillation,” “faecal donor,” “faecal enema,” “faecal reconstitution,” “faecal infusion,” “faecal therapy,” “faecal bacteriotherapy,” “microbiota transplant,” “microbiota transfusion,” “microbiota implantation,” “microbiota implant,” “microbiota instillation,” “microbiota donon,” “microbiota enema,” “microbiota reconstitution,” “microbiota infusion,” “microbiota therapy,” “microbiota bacteriotherapy,” “microflora transplant,” “microflora transfusion,” “microflora implantation,” “microflora implant,” “microflora instillation,” “microflora donor,” “microflora enema,” “microflora reconstitution,” “microflora infusion,” “microflora therapy,” “microflora bacteriotherapy,” “feces transplant,” “feces transfusion,” “feces implantation,” “feces implant,” “feces instillation,” “feces donor,” “feces enema,” “feces reconstitution,” “feces infusion,” “feces therapy,” “feces bacteriotherapy,” “faeces transplant,” “faeces transfusion,” “faeces instillation,” “faeces donor,” “faeces enema,” “faeces reconstitution,” “faeces infusion,” “faeces therapy,” “faeces bacteriotherapy,” “faeces donor,” “faeces enema,” “faeces reconstitution,” “faeces infusion,” “faeces therapy,” “faeces bacteriotherapy,” “stool transplant,” “stool transfusion,” “stool implantation,” “stool implant,” “stool instillation,” “stool donor,” “stool enema,” “stool reconstitution,” “stool infusion,” “stool therapy,” “stool bacteriotherapy,” “flora transplant,” “flora transfusion,” “flora implantation,” “flora implant,” “flora instillation,” “flora donor,” “flora enema,” “flora reconstitution,” “flora infusion,” “flora therapy,” and “flora bacteriotherapy.” The results were then combined using the set operator “AND” with studies identified by varied UC descriptor terms: “ulcerative colitis,” “inflammatory bowel disease,” “colitis,” “ileitis,” “IBD,” and “UC.” We also manually searched proceedings from major international conferences, including the American College of Gastroenterology, Digestive Disease Week, Advances in IBD, United European Gastroenterology Week, Asia Pacific Digestive Week, Congresses of Gastroenterology China and Chinese Congresses of Digestive Diseases from 2010 up to and including September 2015. Additional studies were identified by manually searching the references of articles retrieved from the computerized databases and relevant review articles.

Study Selection and Extraction

Eligibility criteria were determined a priori by the study authors. FMT was defined as administration of a suspension of donor feces (either fresh or frozen) into the gastrointestinal tract for UC treatment. UC was defined by the researchers in studies according to laboratory confirmation, endoscopic evidence and/or clinical symptoms. Efficacy of FMT was assessed by clinical remission. The primary outcome was clinical remission of UC, defined as Mayo score \textless 2.\textsuperscript{3,4,23} or pediatric UC activity index \textless 10.\textsuperscript{10,24} Studies without reported clinical endpoints were excluded. If the study included patients with infections before FMT, they were excluded.

The studies were imported into a bibliographic database to automatically exclude duplicates. Titles, abstracts, and articles were reviewed and assessed by 2 independent reviewers (Sun and Li) based on the eligibility criteria. Data extraction from selected publication used a standardized pretested form. A third party compared the forms of data extraction (Xu and Lu). Any disagreements were corrected by consensus. Demographic data (average age, number of men), pre-FMT therapy, transplantation procedures (route of instillation, FMT dose, numbers of infusions), choice of donor, clinical resolution, adverse events, and duration of follow-up were retrieved. If certain data points were not reported, we contacted with the authors by and obtained the detailed missing data.

Methodology Quality Appraisal

Two authors independently assessed the studies selected for inclusion for methodological quality using 3 methods. The methodological quality of cohort studies was assessed by the National Institute of Clinical Excellence (NICE) quality assessment in keeping with the previous literature (Table 1). The quality of 1 prospective case control study was assessed by the Newcastle-Ottawa Quality Assessment Scale for case-control

| TABLE 1. Quality Assessment of Cohort Studies According to the NICE Checklist |
|-------------------|---|---|---|---|---|---|---|---|---|---|---|---|
| Kunde et al\textsuperscript{24} | – | + | + | + | ? | + | – | 5 |
| Angelberger et al\textsuperscript{52} | – | + | + | + | ? | + | – | 5 |
| Kump et al\textsuperscript{23} | – | + | + | + | ? | + | – | 5 |
| Damman et al\textsuperscript{53} | – | + | + | + | ? | + | – | 5 |
| Suskind et al\textsuperscript{10} | – | – | – | + | ? | + | – | 3 |
| Wei et al\textsuperscript{11} | – | + | + | + | ? | + | – | 5 |
| Cui et al\textsuperscript{12} | – | + | + | + | ? | + | – | 5 |
| Ren et al\textsuperscript{13} | – | + | + | + | ? | + | – | 5 |

NICE checklist used for quality assessment: case series collected in more than 1 center? Is the objective of the study clearly described? Are the inclusion and exclusion criteria clearly reported? Is there a clear definition of the outcome reported? Were data collected prospectively? Is there an explicit statement that the patients were recruited consecutively? Are the main findings of the study clearly described? (8) Are outcomes stratified? +: yes; –: no; ?: unclear. Total NICE score is out of 8. If the answer was “yes” to 4 or more of the criteria listed for high quality, if the answer was “yes” to less than 4 of the criteria listed for lower quality.
| Study | n UC/ n Adults/ Children | Severity | UC Medications | Pre-FMT Therapy | FMT Dosage | FMT Delivery | Number of FMT | Donor Relationship | CR(n) | ER(n) | Adverse Events | Follow-Up (Mo) | Reference Standard of CR |
|-------|--------------------------|----------|----------------|-----------------|------------|-------------|---------------|-------------------|-------|-------|-----------------|-----------------|--------------------------|
| Kunde et al<sup>24</sup> | 9/10 | 6 children and 4 adults | PUCAI between 15 and 65 | Aminosalicylates, biologic therapies, Immunosuppressants, steroids | NR | 70–113 g | Enema | 5 | Unrelated and related | 3 | NR | Cramping, fullness, flatulence, bloating, diarrhea, hematochezia, fever, chills | 1 | PUCAI <10 |
| Angelberger et al<sup>25</sup> | 5/5 | Adults | Mayo score ≥6 | NR | Antibiotics, Probiotics, Bowel lavage | Initially 60 g/250 mL, NJ 17–25 g/250 mL, Enema 6–22 g/100 mL | Nasojejunal + Enema | 3 | Healthy adults | 0 | 0 | Deterioration, Fever, sore throat, flatulence, vomiting | 3 | Mayo score ≤2 with no individual subscore exceeding one point |
| Kump et al<sup>23</sup> | 6/6 | 1 child and 5 adults | Mayo score between 8 and 11 | 5-aminosalicylic acid, Azathioprine, Methotrexate, Prednisolone Infliximab | No | 100–150 g/200–350 mL saline - >total 300–500 mL | Colonoscopy | 1 | Healthy adults | 0 | 0 | Self-limited fever | 12 | Mayo score ≤2 |
| Dammun et al<sup>13</sup> | 7/7 | Adults | UCDAI between 3 and 10 | 5-aminosalicylates | Bowel preparation | 175–290 cc | Colonoscopy | 1 | Healthy adults | 0 | NR | Abdominal cramping and stool output immediately after the FMT, abdominal pain, Bloating, flatulence, vomiting | 3 | UCDAI ≤2 with no individual subscore ≥1 |
| Suskind et al<sup>10</sup> | 4/4 | Children | PUCAI between 20 and 55 | Mesalazine, Azathioprine | Rifaximin 200 mg 3 times daily for 3 days, omeprazole (1 mg/kg orally) vancomycin (500 mg, b.d) bowel preparation | 30 g/100 mL saline | Nasojejunal | 1 | Healthy donor | 0 | NR | Self-limited fever, abdominal distension | 1 | Mayo score <2 |
| Wei et al<sup>11</sup> | 11/14 | Adults | Mayo score of 2–10 | Gatifloxacin, Mesalazine, Gentamicin, Norfloxacin | Metoclopramide, 10 mg esomeprazole magnesium 40 mg intravenously 1wk before FMT, to stop drugs except Mesalazine | 200–300 mL Colonoscopy 100–200 mL Gastroscopy | Endoscopic duodenal and/or colonic infusion | 1–3 | Healthy children | 4 | NR | Self-limited fever and diarrhea | 3–18 | Montreal classification S0 |
| Cui et al<sup>12</sup> | 15/15 | 1 child and 14 adults | Montreal classification (S2 and S3) | | | | | | | | | | |
| Ren et al<sup>13</sup> | 7/7 | Adults | Mayo score ≥6 | Immunosuppressants | metoclopramide 10 mg esomeprazole magnesium 40 mg intravenously 1wk before FMT, to stop drugs except Mesalazine | 200–300 mL Colonoscopy 100–200 mL Gastroscopy | Endoscopic duodenal and/or colonic infusion | 1–3 | Healthy children | 6 | NR | Self-limiting fever, bloating, diarrhea | 6 | Mayo score ≤2 with no individual subscore exceeding 1 point |

CR = Clinical remission, ER = endoscopic remission, NJ = nasojejunal, NR = no report, PUCAI = pediatric ulcerative colitis activity index, UC = ulcerative colitis, UCDAI = ulcerative colitis disease activity index.

<sup>1</sup>The study included the mixed patients (11 UC patients and 3 patients with Crohn disease).
studies that comprised 3 separate parts (selection, comparability, and exposure). For the 2 RCTs, quality was assessed by a modification of the Cochrane approach to determining risk of bias.

Data Analysis

The overall meta-analysis included the clinical remission rates obtained from 9 cohort studies and from the FMT experimental arm of 2 randomized clinical studies and 1 case control study in keeping with the previous literature. We used a fixed-effects model assessing the pooled estimate of clinical remission in the meta-analysis with OpenMeta[Analyst]. Meta-Analyt software (version Beta 3.13; Tufts Medical Center, Boston, MA) was used to construct the funnel plot.

Statistical heterogeneity for each meta-analysis was assessed using the Cochran $Q$ test ($\chi^2$) and $I^2$ method. In the $Q$ test a $P$ value of $>0.1$ was not deemed as statistically significant, it showed that the study was not heterogeneous, and hence we used fixed-effects models; otherwise, we used random-effects models. The $I^2$ method was used to assess the degree of heterogeneity (a score discrimination of 0–40%, 30–60%, 50–90%, and 75–100% was consistent with low, moderate, substantial, and considerable heterogeneity, respectively). Some outcomes were not analyzed but presented in a descriptive way.

RESULTS

Study Selection and Included Studies

Our study search yielded 913 potentially relevant studies. We excluded 141 duplicates and 772 studies based on title and abstract screening. Thirty-four studies were retrieved in full text or abstract. Eleven studies (2 RCTs, 1 open-label case-control study, and 8 cohort studies) met the eligibility criteria. Of the 11 studies, 10 were in full text and 1 was an abstract, and all of them included UC patients for whom there were no infections before FMT. With the exception of 1 study that reported mixed patients (11 UC patients and 3 patients with Crohn disease) (Table 2), all other studies only included UC patients. Among the 23 excluded studies, 10 studies reported UC patients with $C. difficile$ infections, 9 were case reports of UC, and 2 studies studied the unclear definition of UC. Seven studies were considered ‘‘high-quality,’’ while 1 study was classified as ‘‘lower quality’’ (Table 1). None of the studies were multicenter trials that recruited consecutively or stratified the outcomes. All of the studies were prospective and had clear objectives and inclusion/exclusion criteria. Among the 8 cohort studies, the NICE total scores of 7 studies were $\geq 4$, but no study had a maximum NICE total score of 8.

Patients’ Demographics

Eleven studies yielded 133 UC patients with FMT (64 cases in noncontrol cohort studies, 61 cases in 2 RCTs, and 8 cases in an open-label case-control study). Studies included both pediatric and/or adult patients. Among the 133 patients included in the review, 27 (20.3%) were described as having moderate/severe disease, 100 (75.2%) as having mild or mild/moderate disease (Tables 2 and 4), and 6 cases (4.5%) where UC was active (Table 2). Duration of follow-up of patients ranged from 1 month to 18 months with median 3.7 months in 12 studies (Tables 2 and 4).

Fecal Microbiota Transplant of Methodological Characteristics

Data From RCTs

Two small double-blind, randomized (1:1), controlled trials with moderate risk of bias reported use of FMT for patients with mild-to-moderate UC. In the first study, 75 patients (Mayo Clinic score $\geq 4$ with an endoscopic Mayo Clinic score $\geq 1$) received weekly FMT or placebo (water) via retention enema for 6 weeks. Researchers and patients were blinded to the treatment allocation. The primary endpoint was clinical remission, defined as Mayo Score of $<3$ with an endoscopic subscore of 0 at week 7. Six donors (healthy adults) were included in the study, with the majority of subjects receiving FMT from 2 donors (A and B). The Data Monitoring and Safety Committee (DSMB) advised that the trial should be discontinued for futility because the primary end point was unlikely to be achieved as specified in the protocol. At the conclusion of the study, the authors found that patients who received FMT achieved better CR than those receiving placebo (9/38 [24%] vs. 2/37 [5%]; $P = 0.03$). In the second study, 50 UC patients (simple clinical colitis activity index (SCCAI) of $\geq 4$ and $\leq 11$ and stable medication) were treated with either donor stool or autologous FMT (infusion of their own stool) delivered via nasoduodenal tube at baseline and again 3 weeks later. Participants and trial members were blinded to the treatment allocation. Only 37 subjects completed assessment for the primary endpoint, of whom 36 achieved clinical remission (36/37; 97.3%) in the FMT arm vs. 2/37 [5%]; $P = 0.03$).

| Table 3. Quality Assessment of Randomized Controlled Trials |
|-----------------|-----------------|-----------------|
| Rossen et al$^{15}$ | Moayyedi et al$^{14}$ |
| Adequate sequence generation | Unclear | Yes |
| Allocation concealment | Unclear | Yes |
| Blinding of participants, personnel and outcome assessors | Yes | Yes |
| Incomplete outcome data | Yes | Yes |
| Free of selective reporting | Yes | Yes |
| Free of other bias | Yes | Yes |
endpoint, which was also CR defined as SCCAI of ≤2 in combination with ≥1-point improvement on the combined Mayo endoscopic score at week 12. This study was also terminated at interim analysis by the DSMB because of futility. There was no difference in clinical and endoscopic remission between the 2 groups in either the intention-to-treat or per-protocol analyses.

Data From an Open-Label Case-Control Study
An open-label case-control study was included in the review. Fifteen patients (Mayo score ≥4 with an endoscopic Mayo score ≥1) were treated with either FMT (8 patients) or standard therapy (7 patients). Enrolled patients underwent colonoscopy and received 3 administration of FMT using 200 cc of fecal slurry from a healthy donor. The CR was the second endpoint defined as partial Mayo score ≤2 with no subscore ≥1 at 2 weeks. Overall, the authors found that the CR were not significantly different between FMT and standard therapy (3/8 [37.5%] vs. 2/7 [28.6%]).

Data From Noncontrol Cohort Studies
All 8 studies in this category were prospective, noncontrol cohort design. Incomplete data were reported for the donors, preparation, and administration of FMT (Table 2). Eight studies utilized unrelated healthy donors, including 1 study that used healthy children. Two studies used healthy adults, and 1 study did not describe the ages of donors. Two studies used related and unrelated donors. The delivery method included colonic delivery (including enema administration and/or colonoscopic instillation) (n = 4), upper gastrointestinal delivery (including nasogastric/nasojejunal and gastroscopic instillation) (n = 2), and the combination of colonic and upper gastrointestinal delivery (n = 2). The FMT dosage and number of FMT were also variable. The FMT dosage was calculated by the volume of the FMT suspension (containing sterile water or saline) or the weight of stool. The number of FMT ranged from 1 to 6 times among 8 studies.

Meta-Analysis
Eight noncontrol cohort studies and the treatment arms of the clinical control trials were included in a meta-analysis. The pooled proportion of patients who achieved CR was 30.4% (95% CI 22.6–39.4%) (Figure 2). There was low heterogeneity (Cochran Q test, P = 0.139; I² = 33%) (Figure 2).

Subgroup Analyses
Our first subgroup analysis compared the efficacy of upper gastrointestinal delivery (nasogastric/nasojejunal tube and gastroscopy) versus lower gastrointestinal delivery (colonscopy and/or enema). Two studies with the combination of upper and lower gastrointestinal delivery were excluded from this analysis. The rate of CR in patients with the upper gastrointestinal delivery was 27.5% (95% CI 16.1–42.9%) with low heterogeneity between studies (Cochran Q test, P = 0.676; I² = 0%). Six studies used lower gastrointestinal delivery. The rate of clinical remission was 29.8% (95% CI 20.2–41.6%) with low heterogeneity between studies (Cochran Q test, P = 0.231; I² = 27%) (Figure 4 and Table 5).

Our second subgroup analysis compared the efficacy of a single infusion versus multiple infusions (≥1) of FMT. When studies had mixed a single infusion and multiple infusions (≥1), we were able to divide and analyze individual cases, as their raw

### Table 4. Clinical Control Trials of FMT for the Management of UC

| Study | Intervention | Cases | Control | Adverse Events | Follow-up | Outcome |
|-------|--------------|-------|---------|----------------|-----------|---------|
| Ads/Moyes et al. | FMT | 75 | 37 | Abdominal discomfort, fever, transitory fever | 12 | CR (n, %) |
| Ads/Rosen et al. | FMT | 48 | 25 | Abdominal discomfort, fever | 26 | CR (n, %) |
| Ads/Soldatenk et al. | FMT | 15 | 7 | Abdominal discomfort, fever | 12 | CR (n, %) |

CR, clinical remission; NR, no report; SCCAI, short-course corticosteroid use; UC, ulcerative colitis.

Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.
www.md-journal.com | 5
data was available. However if the patients were administered the second FMT due to no efficacy of the first FMT, those were defined as cases with failed a single infusion. The rate of CR in patients with a single infusion was 28.2% (95% CI 10.4–57.0%) with moderate heterogeneity between studies (Cochran Q test, $P = 0.047$; $I^2 = 56\%$). A total of 85 subjects in 6 studies received multiple infusions (>1). The rate of CR was 28.9% (95% CI 20.1–39.7%) with low heterogeneity between studies (Cochran Q test, $P = 0.473$; $I^2 = 0\%$) (Figure 3 and Table 5).

**Sensitivity Analysis**

We excluded the open-label case-control study that was an abstract and the study that was categorized as "lower quality"; and we performed another meta-analysis including other studies, and the CR was 30.4% (95% CI 22.3–39.9%) with moderate heterogeneity between studies (Cochran Q test, $P = 0.087$; $I^2 = 43\%$). The results were similar to the results of the meta-analysis of all studies.

**Adverse Events**

Most of studies showed that FMT was safe (Tables 2 and 4). All of studies reported mild adverse events (including self-limiting fever, abdominal discomfort, abdominal pain, bloating, diarrhea, and vomiting). Two patients’ deterioration of UC was observed 4 weeks after FMT in a study. In a clinical randomized control study, 3 patients with FMT suffered adverse events. Two patients in the FMT group developed patchy inflammation of the colon and also rectal abscess formation, which was resolved by antibiotic therapy. One patient with worsening abdominal discomfort tested positive for *C difficile* toxin after the study.

**DISCUSSION**

To date, this is the largest systematic review and first meta-analysis on FMT in UC patients without infections. We identified 2 RCTs, 1 open-label case-control study, and 8 noncontrol...
cohort studies about the efficacy and safety of FMT in UC patients. According to the 11 studies (8 noncontrol cohort studies and 3 treatment arms of the clinical control trials) in our review, the overall efficacy of FMT was 30.4% (95% CI 22.6–39.4%) in achieving CR, which was significantly higher than the CR of 22% (95% CI 10.4–40.8%) reported by Colman and Rubin. Because few studies were available, Colman and Rubin performed a subgroup analysis with a small sample (including 27 UC cases with FMT in 4 noncontrol cohort studies) and the confidence interval of clinical remission was distinct.

It is worth noting that FMT is not nearly as effective in UC as it is in CDI. In a systematic review and meta-analysis, the efficacy of FMT in patients with *C. difficile* was significantly high at 89.9% (95% CI 84.0–93.3%). These rates are substantially higher than the 30% to 80% CR rates typically reported in various medical therapies for CDI, although direct comparison of such different studies cannot be done with confidence. CDI occurs as a result of outstanding disruption of the indigenous gut microbiota by antibiotics, while UC is a complicated disease with a complex pathologic interplay among immunologic, genetic, environmental, and gut microbial factors. Manipulating the gut microbiota might be an important treatment approach, but not the only 1 strategy for UC. The use of probiotics is the most common approach used by researchers to manipulate microbiota in UC patients. Based on the clinical trial evidence available to date, only *Escherichia coli* Nissle and probiotic mix VSL#3 appear to be effective in the management of UC. The CR rates after using *Escherichia coli* Nissle and probiotic mix VSL#3 were 68% and 49.4%, respectively. Based on limited approaches to manipulate the microbiota in UC patients, FMT with moderate efficacy (30.4% CR rate) might be an alternative approach.

**TABLE 5. Subgroup Analysis for FMT in UC Patients**

| Subgroups                        | Number of Studies (n) | Cases (n) | CR (%)  | 95% Confidence Interval | Tests of Homogeneity |
|----------------------------------|-----------------------|-----------|---------|-------------------------|----------------------|
| FMT delivery modality            |                       |           |         |                         |                      |
| Upper gastrointestinal delivery  | 3                     | 42        | 27.5%   | 16.1–42.9%              | 0% 0.676             |
| Lower gastrointestinal delivery  | 6                     | 79        | 29.8%   | 20.2–41.6%              | 27% 0.231            |
| Times of FMT                      |                       |           |         |                         |                      |
| A single infusion                 | 6                     | 48        | 28.2%   | 10.4–57.0%              | 56% 0.047            |
| Multiple infusions (>1)          | 6                     | 85        | 28.9%   | 20.1–39.7%              | 0% 0.473             |

CR = clinical remission.

* Patients with a single infusion and multiple infusions (>1) in 1 studies were divided into 2 subgroups.

![Funnel Plot](image1)

**FIGURE 3.** Funnel plot of the meta-analysis (all studies).

![Subgroup forest plot](image2)

**FIGURE 4.** Subgroup forest plot of the clinical remission (CR) in different delivery routes.
previous case series and cohort studies. However, results from these 2 RCTs were contradictory because of several differences in their trial design (Table 4). Moayedi et al14 administered 6 FMT infusions via the lower gastrointestinal tract, whereas Rossen et al15 administered 2 FMT infusions via the upper gastrointestinal tract. The delivery routes and number of FMT infusions are critical to the success of FMT, which might affect the overall results. Therefore, we performed subgroup meta-analyses to detect the differences in delivery routes and number of FMT infusions.

In examining subgroup meta-analyses alone in our review, we found significant differences in CR between lower and upper gastrointestinal delivery (29.8% vs. 27.5%, respectively). This result was consistent with that of a RCT in patients with C difficile infection,19 which included 20 patients with C difficile infection compared with colonscopic and nasogastric tube administration of FMT. Those authors found that nasogastric tube administration appeared to be as effective as colonscopic administration. However, Kassam et al22 and Cammarota et al60 reported results that favored FMT by colonoscopy or enema in patients with C difficile infection. Some researchers posit that the upper gastrointestinal route might destroy the active constituent of FMT and render it ineffective by the time it reaches the diseased colon; for example, bacteroidetes might be destroyed by gastric acid.18 However, other authors have argued that many spore-forming firmicutes require transit through the upper gastrointestinal tract in order to be effective.18,25 Since most patients with extensive UC often have a difficult time retaining the infused suspension after FMT via colonoscopy or enema, lower gastrointestinal delivery is suboptimal in this subpopulation of patients.12 In light of these observations, our review identified some researchers who used different ways to decrease the destruction of the active constituent of FMT by delivering the fecal microbiota into mid-gut through endoscopy12 or administering drugs to promote motility of the transplanted fecal microbiota into the colon and to inhibit the secretion of gastric acid.10,12 However, additional high-quality research is needed for further validation of these observations.

In the review, our data found that multiple infusions (>1) had been used in many studies (Tables 2 and 4); thus, we divided patients into subgroups on the basis of the number of infusion of FMT. Patients in whom FMT had been administered multiple times (>1), the rate of clinical remission was 28.9%, while the rate of CR in patients with a single infusion was 28.2%. Although no study reported the efficacy of the number of times and frequency of infusions in the UC patients, the idea is widely recognized that patients with long-standing disease may require several infusions of feces to maintain the infused microbiota in recipients after transplantation stabilized.52 However, better designed studies are needed to investigate this procedural aspect.

Nonetheless, the results from subgroup analyzes are mildly heterogeneous, which considerably limits the applicability of the conclusions.

Admittedly, our review has some methodological and theoretical limitations. First, in the meta-analysis of all included studies, a lower-quality study10 and a study in an abstract format7 were included. Even with sensitivity analysis that provides a similar result, the current results require verification of additional well-designed RCTs and enough power. Second, publication bias was a concern. Because most included studies were noncontrol cohort studies, the authors might have had a desire to publish a series of successfully treated patients, while some clinical failures might have been excluded in the reports that may result in preferential reporting of successful cases. In addition, definitions of variables associated with FMT program were not standard among studies, and publications often did not report data on these variables (e.g., FMT dosage, pre-FMT therapy) (Tables 2 and 4).

Despite these limitations, these data suggest that FMT may be an efficacious and safe alternative therapy for UC, at least when the standard therapy has failed or is unacceptable to the UC patients. The positive findings in our review need to be confirmed and supported by additional well-designed randomized, double-blinded, controlled trials with enough samples. There is an urgent need to develop guidelines to standardize the process of FMT and FMT indication.

ACKNOWLEDGMENT

The authors thank Dr Xia Ke for her valuable comments on writing.

REFERENCES

1. Burisch J, Munkholm P. Inflammatory bowel disease epidemiology. Curr Opin Gastroenterol. 2013;29:357–362.
2. Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142:46–54.
3. Kirsner JB. The historical basis of idiopathic inflammatory bowel diseases. Inflamm Bowel Dis. 1995;1:2–26.
4. Dasgupta S, Kasper DL. Relevance of commensal microbiota in the treatment and prevention of inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:2478–2489.
5. Benjamin JL, Hedin CR, Koutsoumpas A, et al. Randomised, double-blind, placebo-controlled trial of fructo-oligosaccharides in active Crohn’s disease. Gut. 2011;60:923–929.
Fecal Microbiota Transplantation for Ulcerative Colitis

6. Meijer BJ, Dieleman LA. Probiotics in the treatment of human inflammatory bowel diseases: update 2011. J Clin Gastroenterol. 2011;45:S139–S144.

7. van Nood E, Vrieze A, Nieuworp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368:407–415.

8. Bennett JD, Brinkman M. Treatment of ulcerative-colitis by implantation of normal colonic flora. Lancet. 1989;1:164.

9. Scalfaderi F, Pecere S, Bruno G, et al. An open-label, pilot study to assess feasibility and safety of fecal microbiota transplantation in patients with mild-moderate ulcerative colitis: preliminary results. Gastroenterology. 2015;148:S870.

10. Suskind DL, Singh N, Nielson H, et al. Fecal Microbial transplant via nasogastric tube for active pediatric ulcerative colitis. JPGN. 2015;60:27–29.

11. Wei Y, Zhu WM, Gong JF, et al. Fecal microbiota transplantation improves the quality of life in patients with inflammatory bowel discogenic admistration of fecal microbiota to patients with ulcerative colitis. Gastroenterol Res Pract. 2015;2015:1–5.

12. Cui B, Li P, Xu L, et al. Step-up fecal microbiota transplantation strategy: a pilot study for steroid-dependent ulcerative colitis. J Transl Med. 2015;13:298–340.

13. Ren RR, Sun G, Yang YS, et al. A pilot study of treating ulcerative colitis with fecal microbiota transplantation. Zhong Hua Nei Ke Za Zhi (Chinese). 2015;54:411–415.

14. Mosyjedy P, Surette MG, Kim PT, et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology. 2015;149:102–109.

15. Rossen NG, Fuentes S, van der Spek MJ, et al. Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis. Gastroenterology. 2015;149:110–118.

16. Colman RJ, Rubin DT. Fecal microbiota transplantation as therapy for inflammatory bowel disease: a systematic review and meta-analysis. J Crohns Colitis. 2014;8:1569–1581.

17. Anderson JL, Edney RJ, Whelan K. Systematic review: faecal microbiota transplantation in the management of inflammatory bowel disease. Aliment Pharmacol Ther. 2012;36:503–516.

18. Ianio G, Bibbo S, Scalfaderi F, et al. Fecal microbiota transplantation in inflammatory bowel disease: beyond the excitement. Medicine. 2014;93:e97.

19. Sha S, Liang J, Chen M, et al. Systematic review: faecal microbiota transplantation therapy for digestive and nondigestive disorders in adults and children. Aliment Pharmacol Ther. 2014;39:1003–1032.

20. Wells G, Shea B, O’connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2000; http://www.evidencebasedpublichealth.de/download/Newcastle_Ottawa_Scale_Pope_Bruce.pdf (Accessed September 2015).

21. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.

22. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283:2008–2012.

23. Kump PK, Grochening HP, Lackner S, et al. Alteration of intestinal dysbiosis by fecal microbiota transplantation does not induce remission in patients with chronic active ulcerative colitis. Inflamm Bowel Dis. 2013;19:2155–2165.

24. Kunde S, Pham A, Bonczyk S, et al. Safety, tolerability, and clinical response after fecal transplantation in children and young adults with ulcerative colitis. J Pediatr Gastroenterol Nutr. 2013;56:597–601.

25. Kassam Z, Lee CH, Yuan Y, et al. Fecal microbiota transplantation for clostridium difficile Infection: systematic review and meta-analysis. Am J Gastroenterol. 2013;108:500–508.

26. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions version 5.1.0 [updated March 2011]. The cochrane collaboration; 2011. Accessed at www.cochrane-handbook.org on October 1, 2015.

27. Nannini C, West CP, Erwin PJ, et al. Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies. Arthritis Res Ther. 2008;10:R124.

28. Wallace BC, Schmid CH, Lau J, et al. Meta-Analyst: software for meta-analysis of binary, continuous and diagnostic data. BMC Med Res Methodol. 2009;9:80.

29. Deeks J, Higgins J, Altman D, on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group. Chapter 9: Analysing data and undertaking meta-analyses. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008]: The Cochrane Collaboration. 2008.

30. Aas J, Gessert CE, Bakken JS. Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infec Dis. 2003;36:580–585.

31. Borody TJ, Wettstein AR, Leis S, et al. Clostridium difficile complicating inflammatory bowel disease: pre- and post-treatment findings. Gastroenterology. 2008;134:A361.

32. Wettstein A, Borody TJ, Leis SM, et al. Fecal bacteriotherapy— an effective treatment for relapsing symptomatic clostridium difficile infection. In: 15th United European Gastroenterology Week 2007; France 2007.

33. Zainah H, Silverman A. Fecal bacteriotherapy: a case report in an immunosuppressed patient with ulcerative colitis and recurrent Clostridium difficile infection. Case Rep Infect Dis. 2012;2012:810–943.

34. Watson JB, Hahr F, Kelly C. First reported complication of fecal microbiota transplant: ulcerative colitis flare after FMT for relapsing Clostridium difficile infection. Gastroenterology. 2012;142:S540.

35. Annalisa A, Giovanni C, Claudio P, et al. Fecal microbiota transplantation for recurrent C. difficile infection in a patient with chronic refractory ulcerative colitis. J Crohns Colitis. 2015;9:367.

36. Hourigan SK, Chen LA, Grigoryan Z, et al. Microbiome changes associated with sustained eradication of Clostridium difficile after single faecal microbiota transplantation in children with and without inflammatory bowel disease. Aliment Pharmacol Ther. 2015;42:741–752.

37. Espinoza R, Quera R, Meyer L, et al. Fecal microbiota transplantation: first case report in Chile and review. Rev Chil Infectol. 2014;31:477–482.

38. Brace C, Gloor GB, Mark R, et al. Microbial composition analysis of Clostridium difficile infections in an ulcerative colitis patient treated with multiple fecal microbiota transplantations. J Crohns Colitis. 2014;8:1133–1137.

39. DeLeon LM, Watson JB, Kelly CR, et al. Transient flare of ulcerative colitis after fecal microbiota transplantation for recurrent clostridium difficile infection. Clin Gastroenterol Hepatol. 2013;11:1036–1038.

40. Ma CE, Peng NH, Sun QL, et al. Nursing care of fecal microbiota transplantation in one case of ulcerative colitis. J Nurs Sci (Chinese). 2014;29:41–42.

41. Borody TJ, George L, Andrews P, et al. Bowel-flora alteration—a potential cure for inflammatory bowel-disease and irritable bowel syndrome. Med J Australia. 1989;150:604.
42. Borody TJ, Leis S, McGrath K, et al. Treatment of chronic constipation and colitis using human probiotic infusions. In: Probiotics, Prebiotics and New Foods Conference; Universita Urbaniana, Rome; September 2–4, 2001.

43. Borody TJ, Warren EF, Leis S, et al. Treatment of ulcerative colitis using fecal bacteriotherapy. *J Clin Gastroenterol.* 2003;37: 42–47.

44. Vandenplas Y, Veereman G, van dWTBJ, et al. Fecal microbial transplantation in a one-year-old girl with early onset colitis—caution advised. *J Pediatr Gastroenterol Nutr.* 2011;106:352.

45. Borody T, Campbell J, Torres M, et al. Reversal of idiopathic thrombocytopenic purpura [ITP] with fecal microbiota transplantation [FMT]. *Am J Gastroenterol.* 2011;106:S352.

46. Borody TJ, Torres M, Campbell J, et al. Reversal of inflammatory bowel disease (IBD) with recurrent faecal microbiota transplants (FMT). *Am J Gastroenterol.* 2011;106:S366.

47. Ni XD, Li YX, Zhang YL, et al. Enteral nutrition fecal microbiota transplantation via percutaneous endoscopic ecocstomy in treatment of recurrent ulcerative colitis. *CPEN (Chinese).* 2015;22: 29–33.

48. Landy J, Walker AW, Li J, et al. Variable alterations of the microbiota, without metabolic or immunological change, following faecalmicrobiota transplantation in patients with chronic pouchitis. *Sci Rep.* 2015;5:12955.

49. Chunmei Li. Observation and nursing of refractory IBD patients with fecal bacteria transplantation. *Basic Med Forum (Chinese).* 2015;19:2285–2286.

50. Ishikawa D, Osada T, Sasaki T, et al. Alterations of intestinal microbiota in ulcerative colitis patients treated with sequential antibiotic combination and faecal microbiota transplantation. *J Crohns Colitis.* 2015;9(Suppl 1):S364–S365.

51. Wang M, Wang H, Zhang F. Standard fecal microbiota transplantation through mid-gut is effective therapy for refractory ulcerative colitis. *J Gastroenterol Hepatol.* 2013;28(Suppl 3):590.

52. Angelberger S, Reinisch W, Makristathis A, et al. Temporal bacterial community dynamics vary among ulcerative colitis patients after fecal microbiota transplantation. *Am J Gastroenterol.* 2013;108:1620–1630.

53. Danman CJ, Brittnacher MJ, Westerhoff M, et al. Low level engraftment and improvement following a single colonoscopic administration of fecal microbiota to patients with ulcerative colitis. *PLoS One.* 2015;10:e0133925.

54. Drekonja D, Reich J, Gezahgen S, et al. Fecal microbiota transplantation for Clostridium difficile Infection: a systematic review. *Ann Intern Med.* 2015;162:630–638.

55. Britton RA, Young VB. Role of the intestinal microbiota in resistance to colonization by Clostridium difficile. *Gastroenterology.* 2014;146:1547–1553.

56. Fedorak RN. Probiotics in the management of ulcerative colitis. *Gastroenterol Hepatol (N Y).* 2010;6:688–690.

57. Rembacken BJ, Snelling AM, Hawkey PM, et al. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. *Lancet.* 1999;354:635–639.

58. Mardini HE, Grigorian AY. Probiotic mix VSL#3 is effective adjunctive therapy for mild to moderately active ulcerative colitis: a meta-analysis. *Inflamm Bowel Dis.* 2014;20:1562–1567.

59. Youngster I, Sauk J, Pindar C, et al. Fecal microbiota transplant for relapsing Clostridium difficile infection using a frozen inoculum from unrelated donors: a randomized, open-label, controlled pilot study. *Clin Infect Dis.* 2014;58:1515–1522.

60. Cammarota G, Ianiro G, Gasbarrini A. Fecal microbiota transplantation for the treatment of Clostridium difficile infection. A systematic review. *J Clin Gastroenterol.* 2014;48:693–702.